

Appendix 4C

Quarter Ended 31 March 2024

Chimeric Therapeutics Limited

ACN 638 835 828

ASX: CHM

ASX ANNOUNCEMENT **30 APRIL 2024**

QUARTERLY ACTIVITIES REPORT FOR THE PERIOD ENDING 31 MARCH 2024

Sydney, Australia, 30 April 2024: Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 31 March 2024.

Highlights from the quarter included:

- 1st patient in the ADVENT-AML Phase 1B clinical trial in Acute Myeloid Leukemia (AML) receives treatment with CHM 0201
- Key clinical milestones outlined for 2024
- US Patent & Trademark Office allows patent for CORE-NK technology, including the clinical-stage CHM 0201 and preclinical-stage assets CHM 0301, CHM 1301, and CHM 2301
- Cash position significantly strengthened by R&D tax incentive & shortfall placement

1ST PATIENT TREATED IN ADVENT-AML PHASE 1B CLINICAL TRIAL

In February, the first patient was treated in the ADVENT-AML Phase 1B clinical trial, focusing on evaluating Chimeric's CHM 0201 NK cell therapy in conjunction with Azacitidine and Venetoclax for treatment of Acute Myeloid Leukemia (AML) . This trial is an investigator initiated trial taking place at The University of Texas MD Anderson Cancer Center.

The ADVENT-AML trial aims to recruit up to 20 patients with newly diagnosed AML and are ineligible for intensive chemotherapy or allogeneic stem cell transplantation. This initiative will follow a dose confirmation cohort that will examine the safety of combining these treatments for patients with relapsed or refractory AML.

The ADVENT-AML trial is the first clinical trial to evaluate NK cells in combination with the current AML standard of care therapy.

Prior to this Chimeric announced that CHM 0201 cells completed manufacturing and release testing and were provided to MD Anderson to support the ADVENT-AML Phase 1B clinical trial. The CHM 0201 NK cells were manufactured at the Cellular Therapy Integrated Services Laboratory at Case Western Reserve University where the CHM 0201 cells were developed.

KEY CLINICAL MILESTONES FOR 2024

During the quarter, Chimeric recapped its highlights during 2023 while updating shareholders on the key clinical catalysts which are expected for 2024.

Major updates are anticipated to include:

- CHM 1101: Initiation of the Recurrent / Progressive Glioblastoma Phase 1B Expansion Cohort with preliminary data
- CHM 2101: Initiation of Phase 1A Dose Escalation Clinical Trial in Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours with preliminary data
- CHM 0201: Initiation of the ADVENT- AML Phase 1B clinical trial in Acute Myeloid Leaukemia with preliminary clinical data

These milestones, along with those that will advance the Company's next generation technologies, provide meaningful catalysts for value realisation for Chimeric in 2024.

US PATENT ALLOWED FOR CHM 0201 (CORE-NK) PLATFORM TECHNOLOGY

Subsequent to the end of the quarter, the Company announced that the US Patent & Trademark Office has allowed a patent for its CORE-NK technology, including the clinical-stage CHM 0201 and preclinical-stage assets CHM 0301, CHM 1301, and CHM 2301.

The patent, titled "Compositions for Expanding Natural Killer Cells," is anticipated to provide protection until 2039. Chimeric holds an exclusive worldwide license for this patent, applicable to oncology, immune disorders, and infectious diseases. This patent allowance in the United States, the largest global market for biopharmaceuticals, is seen as a foundational element of Chimeric's intellectual property portfolio for its allogeneic NK cell therapy pipeline.

FINANCIAL UPDATES

In January, the Company received a research and development (R&D) tax refund of A$7.36m under the Australian Government's R&D tax incentive. The refund is in recognition of Chimeric's R&D activities during the 2023 financial year and will provide important funding for continued development of its portfolio of cell therapies. The Australian Government R&D tax incentive program provides companies engaging in eligible activities with a refundable tax offset of up to 43.5%.

Also during January, Chimeric announced it had raised a further $3.2m in a placement of the shortfall corresponding to the non-renounceable entitlement offer announced in October 2023. The shortfall was issued at the same price per share as the entitlement offer, being $0.028 per share. On completion of the placement of the shortfall, the entitlement offer raised a total of approximately $7.66m (before costs).

To begin the period, the Company also announced that it had secured an additional $1 million investment from Lind Global Fund II, LP, managed by The Lind Partners, under the terms previously set in June 2023. This funding is part of a placement agreement that includes an advance payment, a commitment fee, and the issuance of further options.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 current clinical programs and plans to open additional clinical programs in 2024.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM 2101 (CDH17 CAR T) is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer. CHM 2101 (CDH17 CAR T) received FDA IND clearance in late 2023 with a Phase 1A clinical trial which will study patients with colorectal cancer, gastric cancer and neuroendocrine tumours, planned for initiation mid-2024.

CHM 0201 (CORE-NK platform) is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CHM 0201 in combination regimens have been initiated. From the CHM 0201 platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

CONTACT

Investors

Jennifer Chow
Chief Executive Officer and Managing Director
Chimeric Therapeutics
T: + 1 9087238387
E: jchow@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Paul Hopper
Executive Chairman
Chimeric Therapeutics
T: + 61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Chimeric Therapeutics Limited	
ABN	**Quarter ended ("current quarter")**
68 638 835 828	31 March 2024

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (9 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers (inclusive of GST)	-	5,475
1.2	Payments for (inclusive of GST)		
	(a) research and development	(2,386)	(6,683)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs*	(1,304)	(4,964)
	(f) administration and corporate costs	(758)	(2,565)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	52	75
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	7,337	7,337
1.8	Other (provide details if material)	68	(324)
1.9	**Net cash from / (used in) operating activities**	**3,009**	**(1,649)**

*Staff costs includes staff, directors, scientific advisors and employment related costs.

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**-**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	4,172	11,740
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(377)	(1,165)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other – payments of licence fee liabilities	(534)	(1,444)
3.10	**Net cash from / (used in) financing activities**	**3,261**	**9,131**

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	3,525	2,363
4.2	Net cash from / (used in) operating activities (item 1.9 above)	3,009	(1,649)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	3,261	9,131
4.5	Effect of movement in exchange rates on cash held	72	22
4.6	**Cash and cash equivalents at end of period**	**9,867**	**9,867**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	9,867	3,525
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**9,867**	**3,525**

6.	**Payments to related parties of the entity and their associates**	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	450
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Item 6.1 – Include payments for remuneration of director fees to executive and non-executive directors in the normal course of business at commercial rates, excluding reimbursements of out-of-pocket expenses.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	3,009
8.2	Cash and cash equivalents at quarter end (item 4.6)	9,867
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	9,867
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	N/A

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 30 April 2024

Authorised by: The Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

Phone +61 3 98245254
Email info@chimerictherapeutics.com

Chimeric Therapeutics Limited

ACN 638 835 828

ASX: CHM

CHIMERIC
THERAPEUTICS